Disclaimer

This entry is for professional discussion and educational reflection only. It does not constitute individual medical advice, formal guideline instruction, or a recommendation to deviate from local hepatobiliary, microbiology, or interventional radiology protocols. Clinical decisions should always be based on the individual patient, imaging findings, microbiology results, senior multidisciplinary input, and local policy. Some details of the clinical prompt that inspired this article have been deliberately generalised.

Introduction

Every now and again, a junior doctor asks a question that is either wonderfully insightful, mildly inconvenient, or both.

This week one of our F1s asked whether antibiotics can be given directly into a liver abscess cavity.

My immediate answer was the professionally polished version of: I have not heard of that before. Which, in hospital medicine, can mean anything from “absolutely not” to “there is probably a 2003 case report from somewhere obscure that nobody on the ward round has read”.

So I went looking.

The short answer is that direct intracavitary administration of antibiotics into a liver abscess has been described, but the evidence base is sparse, largely case-based, and nowhere near strong enough to call it standard practice. In the UK and Europe in particular, modern management of pyogenic liver abscess remains firmly centred on systemic antibiotics, source control, and image-guided drainage where needed, rather than local antibiotic instillation (Bosanko et al., 2011; Neill et al., 2019; Serraino et al., 2018; Wendt et al., 2024).

Why the idea is not ridiculous

At first glance, the idea of putting antibiotics directly into an abscess cavity sounds slightly dramatic, perhaps the sort of intervention dreamt up at 03:00 when the scan still looks awful and everybody is pretending to be calm.

Yet the biological logic is not silly at all. Abscesses are hostile spaces. They contain necrotic debris, thick purulent material, variable loculation, poor vascular supply and altered pH, all of which may impair the penetration and activity of systemically administered antibiotics.

Wagner, Sauermann and Joukhadar (2006) highlighted this broader pharmacological problem in their discussion of antibiotic penetration into abscess fluid, supporting the principle that therapeutic concentrations inside abscess cavities may be inconsistent.

That matters because conventional management assumes two things: first, that antimicrobials can reach the infected compartment sufficiently, and second, that drainage will adequately reduce bacterial burden and improve antimicrobial access.

Most of the time that works. Sometimes, however, collections remain thick, multiloculated, poorly draining, or microbiologically persistent despite apparently appropriate treatment. It is in this awkward grey zone that local antibiotic instillation becomes conceptually attractive.

What standard care still looks like

Despite that theoretical appeal, current real-world management in the UK and Europe remains conventional. Bosanko et al. (2011), reviewing 73 patients in a UK centre, found that percutaneous drainage and systemic antibiotics formed the backbone of treatment.

Neill et al. (2019), in a London cohort examining both pyogenic and amoebic liver abscesses, likewise described management through antimicrobial therapy, drainage strategy, and microbiological characterisation rather than direct intracavitary antibiotic therapy.

Serraino et al. (2018), reporting European experience, showed early antibiotic use in all patients and procedural intervention in a substantial proportion, again without positioning local antibiotic instillation as routine therapy.

More recently, Wendt et al. (2024), in a German tertiary-centre cohort, emphasised adequate anti-infective therapy and early invasive intervention, with no suggestion that direct cavity administration is mainstream practice.

That is important in itself. When multiple contemporary cohorts discuss liver abscess treatment in detail yet do not identify intracavitary antibiotics as a standard option, that silence is not accidental. It strongly suggests that this is not routine practice in the UK or most of Europe.

The direct evidence for intracavitary antibiotics

The strongest liver-specific evidence I found remains very limited. Alvarez-Uria et al. (2013) reported two cases of pyogenic liver abscess treated with systemic antibiotics plus local meropenem instillation through an ultrasound-guided percutaneous catheter after incomplete drainage.

The authors argued that direct antibiotic delivery may maintain high local concentrations within the abscess cavity, potentially improving treatment in refractory cases. Both patients improved, and the report concluded that local beta-lactam instillation could be safe and effective.

That wording matters. Could is doing a lot of work there.

A two-patient case report is useful for showing feasibility, but it cannot establish comparative efficacy, define indications, or tell us whether the same patients might have improved with repeated drainage, different catheter positioning, prolonged intravenous therapy, or simply more time. It is signal, not proof.

There is also a pediatric case report by Steele (2021), describing a 15-year-old with a large multiloculated Staphylococcus aureus liver abscess that had failed to resolve despite drainage and intravenous antibiotics. Daily intra-abscess oxacillin was administered for seven days, after which the patient improved markedly and the abscess resolved on follow-up imaging. Again, interesting, plausible, and clinically memorable. Also again: one patient, unusual context, low-level evidence.

Related but not identical evidence

There is some adjacent literature that broadens the picture. Dull et al. (2000) described non-surgical treatment of biliary liver abscesses using endoscopic drainage plus local antibiotic lavage via a nasobiliary catheter.

Outcomes were favourable in most biliary cases, suggesting that regional antibiotic delivery into an infected hepatobiliary system can be technically feasible and clinically useful.

However, that is not quite the same as percutaneous instillation into a mature liver abscess cavity as a modern rescue strategy. The anatomical route, pathology, and procedural context differ. It supports the principle of local delivery, but not routine direct translation into present-day abscess protocols.

Interestingly, some European investigators have focused not on local antibiotics, but on improving cavity drainage by other means.

Cadar et al. (2021), in a Romanian case series, reported the use of intracavitary acetylcysteine during percutaneous drainage of large multiloculated liver abscesses. Their rationale was that the real obstacle in some patients is not primarily antibiotic choice but poor evacuation of thick or loculated material.

That line of thinking is clinically persuasive. In difficult abscesses, the enemy is often failed source control rather than merely inadequate antimicrobial exposure.

UK and European practice versus other parts of the world

One of the original questions was whether this strategy appears more common elsewhere. The answer seems to be: possibly more reported outside the UK and Europe, but still far from standard anywhere.

Contemporary Western cohorts continue to describe liver abscesses primarily through the framework of systemic antimicrobials and drainage, often in the setting of biliary disease, enteric organisms, mixed flora, streptococci, enterococci, and Escherichia coli (Bosanko et al., 2011; Serraino et al., 2018; Wendt et al., 2024).

By contrast, literature from parts of Asia has long highlighted the major role of Klebsiella pneumoniae, including hypervirulent syndromes and metastatic spread. Wendt et al. (2024) specifically note that such hypervirulent Klebsiella patterns are much more prominent in Asian settings than in Europe or North America.

That epidemiological difference may influence therapeutic experimentation. Where disease burden is higher, case complexity differs, and local procedural traditions vary, unusual adjunctive strategies may be described more readily.

But even there, high-quality comparative evidence for direct intracavitary antibiotic instillation remains absent.

So, does it work?

The uncomfortable but honest answer is: it may work in selected refractory cases, but we do not know whether it works better than the alternatives.

There is a pharmacological rationale. There are successful case reports. There is some adjacent literature suggesting local lavage or adjunctive intracavitary treatment can help in difficult hepatobiliary infections.

But there are no robust randomised trials, no convincing comparative cohort studies, and no clear UK or European guideline pathway recommending routine intracavitary antibiotic administration for pyogenic liver abscess.

Curran et al. (2023), in their systematic review of antibiotic durations for pyogenic liver abscess, highlighted the broader problem: even the ordinary antibiotic questions in liver abscess management remain poorly standardised.

If we still lack consensus evidence on something as basic as duration, it is hardly surprising that direct cavity instillation sits far outside mainstream evidence-based practice.

Final thoughts

So, what should one say when asked whether antibiotics can be administered directly into a liver abscess cavity?

Probably this: yes, it has been done. It is biologically plausible. It appears in the literature as a rescue or salvage strategy in cases where standard drainage and systemic antibiotics have not been enough. But no, it is not standard UK practice, not well supported by modern comparative evidence, and not something to reach for casually without senior hepatobiliary, microbiology, and interventional radiology input.

In other words, this is not complete nonsense. It is simply not established medicine.

Which, to be fair, describes quite a lot of interesting ideas that first appear in hospitals between a ward round, an awkward CT report, and somebody saying, “I’ve never seen it done, but…”

References

Alvarez-Uria, G., Pakam, R., Midde, M. and Naik, P.K. (2013) ‘Intra-abscess administration of antibiotics through ultrasound-guided percutaneous catheter for the treatment of pyogenic liver abscess’, Journal of Clinical and Diagnostic Research, 7(8), pp. 1698–1699.

Bosanko, N.C., Chauhan, A., Brookes, M., Moss, M. and Wilson, P.G. (2011) ‘Presentations of pyogenic liver abscess in one UK centre over a 15-year period’, Journal of the Royal College of Physicians of Edinburgh, 41(1), pp. 13–17.

Cadar, R., Trofin, A.-M., Zabara, M., Nastase, M., Fotea, V., Lupascu-Ursulescu, C., Livadaru, C. and Lupascu, C. (2021) ‘The use of mucolytic agent in percutaneous drainage of liver abscess: a case-series analysis’, Chirurgia, 116(4), pp. 473–480.

Curran, J., Lam, J.C., Vallance, A.E., Parkins, M.D. and Stokes, W. (2023) ‘Antibiotic treatment durations for pyogenic liver abscesses: a systematic review’, PLoS One, 18(11), e0293571.

Dull, J.S., Topa, L., Balgha, V. and Pap, A. (2000) ‘Non-surgical treatment of biliary liver abscesses: efficacy of endoscopic drainage and local antibiotic lavage with nasobiliary catheter’, Gastrointestinal Endoscopy, 51(1), pp. 55–59.

Neill, L., Edwards, F., Collin, S.M., Harrington, D., Wakerley, D., Rao, G.G. and McGregor, A.C. (2019) ‘Clinical characteristics and treatment outcomes in a cohort of patients with pyogenic and amoebic liver abscess’, BMC Infectious Diseases, 19, 490.

Serraino, C., Elia, C., Bracco, C., Rinaldi, G., Pomero, F., Silvestri, A., Fenoglio, L. and Ponzo, P. (2018) ‘Characteristics and management of pyogenic liver abscess: a European experience’, Medicine, 97(19), e0628.

Steele, R.W. (2021) ‘Treatment of a large multiloculated liver abscess with intra-abscess antibiotic instillation’, The Pediatric Infectious Disease Journal, 40(1), pp. 83–84.

Wagner, C., Sauermann, R. and Joukhadar, C. (2006) ‘Principles of antibiotic penetration into abscess fluid’, Pharmacology, 78(1), pp. 1–10.

Wendt, S., Lübbert, C., Karlas, T. and colleagues (2024) ‘Clinical management, pathogen spectrum and outcomes in patients with pyogenic liver abscess in a German tertiary-care hospital’, Scientific Reports, 14, Article 63819.